Fig. 1
![Fig. 1](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12916-018-1011-0/MediaObjects/12916_2018_1011_Fig1_HTML.gif)
Therapeutic scenario for patients with advanced non-squamous ‘undruggable’ NSCLC (EGFR wild type, ALK and ROS1 non-rearranged, PD-L1 < 50%)
Therapeutic scenario for patients with advanced non-squamous ‘undruggable’ NSCLC (EGFR wild type, ALK and ROS1 non-rearranged, PD-L1 < 50%)